AbbVie Management
Management criteria checks 2/4
AbbVie's CEO is Robert Michael, appointed in Jul 2024, has a tenure of less than a year. total yearly compensation is $14.44M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth $17.52M. The average tenure of the management team and the board of directors is 1.3 years and 12 years respectively.
Key information
Robert Michael
Chief executive officer
US$14.4m
Total compensation
| CEO salary percentage | 9.9% |
| CEO tenure | less than a year |
| CEO ownership | 0.006% |
| Management average tenure | 1.3yrs |
| Board average tenure | 12yrs |
Recent management updates
Recent updates
Betting Big On AbbVie: A Prescription For Growth And Dividends
Dec 11AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.64
Dec 09
AbbVie: Upgrading To 'Strong Buy' After Pullback
Nov 22AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64
Nov 19AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
Nov 12AbbVie Stock: Keep Calm And Buy The Dip
Nov 11AbbVie: 3 Positives From The Earnings Report
Oct 30AbbVie: Strong Dividends But Humira Disappoints
Oct 22AbbVie: Dividend Discount Model Suggests Large Valuation Risks
Sep 29We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt
Sep 06Why AbbVie Remains One Of My Favorite Dividend Growers
Aug 27AbbVie: Growth Is Still A Better Choice
Jul 29AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note
Jul 17AbbVie: A Hold Again (Rating Downgrade)
Jul 03Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)
Jun 28AbbVie: 5 Reasons That Make A Buy Case
Jun 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$5b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$14m | US$1m | US$5b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$9b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$10m | US$1m | US$12b |
| Sep 30 2022 | n/a | n/a | US$13b |
| Jun 30 2022 | n/a | n/a | US$13b |
| Mar 31 2022 | n/a | n/a | US$12b |
| Dec 31 2021 | US$12m | US$1m | US$11b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$7b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$13m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$9m | US$907k | US$8b |
| Sep 30 2019 | n/a | n/a | US$3b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$5b |
| Dec 31 2018 | US$3m | US$554k | US$6b |
Compensation vs Market: Robert's total compensation ($USD14.44M) is about average for companies of similar size in the US market ($USD12.87M).
Compensation vs Earnings: Robert's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Robert Michael (54 yo)
less than a year
Tenure
US$14,441,320
Compensation
Mr. Robert A. Michael served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as its CEO and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 12yrs | US$25.66m | 0.022% $ 69.1m | |
| CEO & Director | less than a year | US$14.44m | 0.0056% $ 17.5m | |
| Executive VP & CFO | 2.6yrs | US$10.19m | 0.00087% $ 2.7m | |
| Executive VP & COO | less than a year | US$9.30m | 0.011% $ 35.6m | |
| Executive VP & Chief Commercial Officer | no data | US$15.35m | 0.0035% $ 11.1m | |
| Executive VP of Research and Development & Chief Scientific Officer | less than a year | no data | 0.00092% $ 2.9m | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 2.3yrs | no data | 0% $ 0 | |
| Senior VP | 1.3yrs | no data | no data | |
| Executive VP & Chief Human Resources Officer | no data | US$3.30m | 0.00078% $ 2.4m | |
| Senior VP of AbbVie & President of Oncology | 1.3yrs | no data | no data | |
| Executive VP and Chief Business & Strategy Officer | 2yrs | no data | 0.0032% $ 9.9m |
1.3yrs
Average Tenure
55yo
Average Age
Experienced Management: ABBV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 12yrs | US$25.66m | 0.022% $ 69.1m | |
| CEO & Director | less than a year | US$14.44m | 0.0056% $ 17.5m | |
| Lead Independent Director | 12yrs | US$388.39k | 0.00065% $ 2.0m | |
| Independent Director | 4.7yrs | US$389.98k | 0.0071% $ 22.3m | |
| Independent Director | 12yrs | US$421.58k | 0.0014% $ 4.4m | |
| Independent Director | 12yrs | US$394.98k | 0.00090% $ 2.8m | |
| Independent Director | 12yrs | US$377.48k | 0% $ 0 | |
| Independent Director | 12yrs | US$369.98k | 0.00011% $ 345.4k | |
| Independent Director | 7.7yrs | US$369.98k | 0% $ 0 | |
| Independent Director | 9yrs | US$384.98k | 0% $ 0 | |
| Independent Director | 6.7yrs | US$359.98k | no data | |
| Independent Director | 12yrs | US$461.18k | 0.000010% $ 31.4k |
12.0yrs
Average Tenure
70yo
Average Age
Experienced Board: ABBV's board of directors are seasoned and experienced ( 12 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 22:35 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AbbVie Inc. is covered by 54 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Luisa Hector | Berenberg |